238 results about "Neurological Damage" patented technology

The invention relates to Pediococcus pentosaceus PP90 for preventing and treating alcoholic nerve injury and application of the Pediococcus pentosaceus PP90, the Pediococcus pentosaceus PP90 is preserved in China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC NO.32034. The Pediococcus pentosaceus PP90 can be used for preventing and treating alcoholic nerve injury. The fermentation product of the pediococcus pentosaceus PP90 can degrade the alcoholic strength of alcohol, can generate ethanol dehydrogenase and acetaldehyde dehydrogenase, can improve the activity of nerve cells, can regulate the expression of cytokines, can inhibit the activation of astrocytes, can regulate the expression of brain-derived neurotrophic factors, and can inhibit the growth of the brain-derived neurotrophic factors. The compound can improve the disordered neurotransmitter level, and can be used for preparing products for preventing or improving alcoholic nerve injury.

The invention discloses a self-adaptive adjustment nerve electrophysiology monitoring device for an orthopedic tumor operation, and belongs to the technical field of medical equipment. The system comprises a signal acquisition module, a signal feature extraction module, a self-adaptive adjustment control module and an intraoperative feedback early warning module, the signal feature extraction module carries out multi-angle feature extraction on neural signals and accurately identifies changes of neural states in a complex signal environment, and the self-adaptive adjustment control module dynamically adjusts monitoring and stimulation strategies according to changes of real-time neural signals in an operation, compares pre-operation baseline signals with the real-time signals in the operation, and determines whether the neural states are changed or not according to the pre-operation baseline signals and the real-time signals in the operation. The change trend of the nerve state is accurately judged, whether the nerve signal is in the normal physiological fluctuation range or not is evaluated, the intra-operation feedback early warning module converts the nerve signal into visual and auditory feedback, the perception ability of an operator to the nerve state is improved, the nerve injury risk is dynamically evaluated, and the operation safety is improved. And according to the risk level, different levels of early warning mechanisms are triggered, and an operator is suggested to adjust an operation strategy.

The invention relates to pediococcus acidilactici PA27 capable of degrading alcohol and improving alcoholic nerve injury and application of the pediococcus acidilactici PA27, the pediococcus acidilactici PA27 is preserved in China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC NO.31922. The pediococcus acidilactici PA27 can degrade alcohol and improve alcoholic nerve injury. The pediococcus acidilactici PA27 separated and screened by the invention can grow and propagate in an alcohol-containing culture medium, can degrade alcohol and can generate ethanol dehydrogenase and acetaldehyde dehydrogenase; the polypeptide can be used for constructing a blood-brain barrier and reducing the damage of alcohol to central nervous cells; the traditional Chinese medicine composition can reduce the expression of inflammatory cytokines TNF-alpha, inhibit the activation of astrocytes, promote the expression of brain-derived neurotrophic factors BDNF, regulate the release of alcohol-induced astrocyte neurotransmitters and improve alcoholic nerve injury.

The invention relates to the technical field of bioactive peptides, and discloses a walnut peptide with a neuroprotection function and a preparation method and application thereof, and predicts that a batch of small molecular walnut peptides have the neuroprotection function through enzymolysis of natural walnut protein, molecular weight screening and molecular docking. Experiments prove that the walnut peptide disclosed by the invention has a nerve protection function: the cell activity of nerve cells is improved, and the walnut peptide plays a role in preventing neurodegenerative diseases and other nerve-related diseases; the toxic effect of oxidative damage on nerve cells is relieved, nerve cell apoptosis is inhibited, the cell viability of the nerve cells is improved, and the function of treating nerve injury related diseases is achieved; the compound can be used for improving the activity of nerve cells, relieving oxidative damage of the nerve cells, adjusting the protein level of nerve damage related pathways, preparing related drugs for reducing blood pressure or resisting senile dementia or tumors and the like, and has a wide application prospect.

The invention relates to the technical field of related drugs for nerve injury caused by heavy metal pollution, in particular to application of a compound for inhibiting phosphorylation of ARMC10 in preparation of drugs for antagonizing tin-induced nervous system injury. Exposure of trimethyltin chloride induces nerve cell mitochondrial dysfunction, and the key mechanism is ARMC10 serine 43 site abnormal phosphorylation. Phosphorylated protein causes excessive mitochondrial fission, membrane potential collapse and energy metabolism disorder, resulting in neuron damage. Based on the target spot, a compound for antagonizing tin-induced nervous system injury is obtained through screening, protein phosphorylation can be specifically inhibited, mitochondrial dynamic unbalance and dysfunction induced by trimethyltin chloride are effectively reversed, and neurotoxicity is relieved. According to the technical scheme, the technical problem that in the prior art, no medicine for effectively antagonizing tin-induced nervous system injury exists can be solved, and the compound has the application potential for treating the nervous system injury and cognitive impairment caused by tin exposure.

The invention provides a culture method, application and detection method of mesenchymal stem cells for treating nervous system diseases, and belongs to the technical field of biological medicines. The invention provides a culture medium of mesenchymal stem cells, a method for culturing and subculturing the mesenchymal stem cells by using the culture medium, and a method for detecting the biological efficacy of the mesenchymal stem cells for treating nervous system diseases. The mesenchymal stem cell preparation disclosed by the invention has a relatively good treatment effect on nervous system diseases, and can be used for improving the new object recognition capability and the cerebral infarction range, inhibiting the release of inflammatory factors, reducing the oxidative stress level and narrowing the spinal cord lesion range so as to improve nervous system injury.

The invention relates to the field of remote quality control of kinesio, and provides a remote kinesio treatment guidance and quality control system. The image acquisition module is used for acquiring high-definition image data of a to-be-treated area through intelligent terminal equipment and marking anatomical feature points; wherein the high-definition image data comprises a static image and a dynamic muscle movement video stream; the AI analysis engine is used for carrying out feature extraction on the high-definition image data based on a muscle dynamics model of a to-be-treated region constructed by a convolutional neural network, identifying a muscle tension abnormal region and grading a nerve injury degree, and generating an initial sticking path recommendation scheme; the remote auditing interface transmits the recommended scheme generated by the AI to the doctor end interaction interface, obtains a target treatment scheme after the doctor end performs scheme correction based on the medical history data of the patient, and confirms a final treatment instruction through a digital signature; and the block chain quality control module is used for encrypting key operation data in the treatment process and then writing the key operation data into a distributed account book to generate a treatment process traceability chain which cannot be tampered.

The invention discloses a silk fibroin-hyaluronic acid temperature-sensitive bioactive hydrogel scaffold, a preparation method thereof and application of the silk fibroin-hyaluronic acid temperature-sensitive bioactive hydrogel scaffold in TBI treatment, hyaluronic acid, silk fibroin and N-isopropylacrylamide are used as raw materials to construct temperature-sensitive hydrogel, and bone marrow mesenchymal stem cells (BMSCs) and paeoniflorin (PF) are loaded to form a treatment unit. Hyaluronic acid is one of components of an extracellular matrix (ECM), has high affinity to cells, and can promote proliferation of stem cells. Silk fibroin has high biocompatibility and biodegradability and good mechanical strength and ductility / toughness, and can promote tissue repair and stem cell attachment and proliferation. N-isopropylacrylamide endows the hydrogel with the characteristic of in-situ temperature-sensitive gelling. Therefore, the bioactive hydrogel stent has the advantages of components, combines the BMSCs and the PF, overcomes the obstacle that the medicine is limited by BBB to be transferred into the brain, and is implanted into a brain injury part after a TBI surgical operation to be used for repairing and treating nerve injury.

The invention belongs to the technical field of microorganisms, and relates to lactobacillus acidophilus LA4 and application thereof. The classification name of the lactobacillus acidophilus LA4 is lactobacillus acidophilus, the lactobacillus acidophilus LA4 is preserved in the China General Microbiological Culture Collection Center (CGMCC) on July 9, 2025, and the preservation number of the lactobacillus acidophilus LA4 is CGMCC No.35144; the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The strain can significantly improve cognitive impairment of an elderly behavior cognitive impairment model mouse and enhance the learning and memory ability of the mouse by reducing deposition of beta amyloid protein in the brain of the mouse, inhibiting the activity of acetylcholin esterase, regulating and controlling the neurotransmitter level, relieving brain inflammatory response, reducing nerve injury, promoting synaptic regeneration and the like. The strain provided by the invention provides a potential treatment scheme for preventing or improving senile behavioral cognitive impairment, and has important development and application values.

The invention can provide compounds, analogs of blebbistatin, effective and selective inhibitors of nonmuscle myosin II relative to cardiac myosin II. Compounds can be used in the method of treating a disease, disorder, or medical condition in a patient, comprising modulating myosin II ATPase, such as treatment of substance abuse relapse disorder, or of renal disease, cancer and metastasis, benign prostate hyperplasia, hemostasis or thrombosis, nerve injury including retinal damage, lung fibrosis, liver fibrosis, arthrofibrosis, wound healing, spinal cord injury, periodontitis, glaucoma and immune-related diseases including multiple sclerosis; or wherein the disease, disorder, or medical condition comprises addiction including abuse of or addiction to anything classified as a Substance-Related or Addictive Disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM), such as, but not limited to, cocaine, opioids, amphetamines, ethanol, cannabis / marijuana, nicotine, and activities including gambling.Compounds are of general formulawith substituents as defined herein.

The invention provides a self-assembled temperature-sensitive hydrogel for neural restoration and a preparation method thereof. The hydrogel comprises the following raw materials: poloxamer, an acellular matrix and a neural factor in a mass concentration ratio of (5-10): (10-20): (1-4), preferably 5: 15: 1. The preparation method comprises the following steps: respectively preparing a poloxamer solution and an acellular matrix solution, mixing and heating the poloxamer solution and the acellular matrix solution to form a double-network three-dimensional gel structure, adding the nerve factors, stirring or ultrasonically dispersing, and heating to form the bioactive hydrogel. The hydrogel can rapidly form a stable three-dimensional structure at the body temperature, a support is provided for nerve repair, cell adhesion and proliferation are supported, and the added nerve factors are beneficial to maintaining the activity of neurons. Meanwhile, the hydrogel is in a liquid state at a low temperature, is convenient to inject, is fixed at a body temperature, is adjustable in degradation rate, is non-toxic, is suitable for local nerve injury treatment, and improves the bioavailability and safety of a nerve repair material.

The invention relates to a stroke prognosis prediction model training method based on quantum computing and artificial intelligence, and relates to the technical field of prognosis effect prediction. According to the method, leukocyte community parameters are introduced into an acute ischemic stroke prognosis model for the first time, morphological function characteristics of leukocytes are detected through a flow cytometry, and compared with traditional inflammation indexes, the leukocyte prognosis model has higher sensitivity and objectivity and becomes an important index for predicting neurological function impairment; the indexes closely related to cerebral apoplexy prognosis are screened out through quantum calculation for the first time, and a new thought is provided for high-dimensional data feature screening; meanwhile, by comparing 14 traditional machine learning, integrated learning and deep learning models, it is judged that the LightGBM model is an acute ischemic stroke prognosis prediction model, and compared with the prior art, the LightGBM model is remarkably improved.

The invention relates to a polypeptide and use thereof in treating stroke and other neurological injury-related diseases or use thereof in health care products.

The invention discloses a method for inducing dorsal root node satellite glial cells to be reprogrammed into neurons by using a small molecule compound and application of the method. The small molecule compound composition is prepared from ISX-9, RO4929097, CHIR99021, VPA, RepSox, Forskolin, SC79 and VC, and growth factors BDNF, GDNF, NT-3 and NGF beta, neuron culture additives B27 and N2 additives are added at the same time, so that survival and maturation of neurons are promoted and induced. Wherein each component is a safe and low-cost small molecule compound and a neurotrophic factor, and the pharmaceutical composition and the growth factor can be used for reprogramming rat dorsal root ganglion satellite glial cells into neurons with specific phenotypes and functional characteristics in vitro. And a new seed cell is provided for basic research of clinical nerve injury diseases and clinical cell treatment development.

The invention provides a fluorescent probe compound for simultaneously detecting HClO and ONOO <-> at two sites as well as preparation and application of the fluorescent probe compound. According to the probe compound, N, N-dimethylaminothioformyl ester is used as a response group of HClO, and the fluorescent probe RhB-ClO for simultaneously detecting HClO and ONOO <-> is constructed by expanding a conjugated structure of rhodamine. The probe shows excellent selectivity, high sensitivity (the detection limits are 9.9 nM and 13.1 nM respectively), good light stability and real-time responsiveness (the response time is 30 s and 150 s respectively) on HClO and ONOO <->. The probe not only can realize dual-channel imaging of HClO and ONOO <-> under oxidative stress conditions, but also can visualize the ferroptosis process of cells, a Parkinson's disease model and changes of HClO and ONOO <-> levels in an APAP-induced liver injury model. In addition, RhB-ClO can also be used for screening potential candidate drugs for nerve injury and liver injury, and it is proved that luteolin and piplongumine can be used as candidate antioxidant drugs.

The invention provides a pharmaceutical composition for treating Alzheimer's disease. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 10-15 parts of ginseng, 10-15 parts of rhizoma acori graminei, 10-15 parts of polygala tenuifolia, 15-20 parts of rhizoma polygonati, 15-20 parts of ginkgo leaves and 5-10 parts of schisandra chinensis. Therefore, the ginseng and the ginkgo leaves jointly regulate a cholinergic system and cerebral blood flow, and the cognitive function is enhanced; the rhizoma acori graminei and the ginkgo leaves cooperate to inhibit aggregation of beta-amyloid protein, improve cerebral circulation and relieve neurotoxicity. Polygonatum sibiricum and Chinese magnoliavine fruit protect nerve cells through anti-oxidation and anti-inflammatory effects and reduce nerve injury. Schizandrin further stabilizes a neurotransmitter system and enhances the synergistic effect of other medicinal materials, a multi-layer treatment network of Abeta deposition inhibition, cholinergic system regulation, anti-inflammation and anti-oxidation and nerve protection is integrally formed, and the core pathological link of the Alzheimer's disease is comprehensively intervened, so that the cognitive function is improved, and the disease progress is delayed.

The invention discloses application of an NR1D1 protein phosphorylation site in preparation of cerebral hemorrhage treatment drugs, and belongs to the technical field of molecular biology. According to the invention, the specific phosphorylation site and phosphorylation modification level of the NR1D1 protein are determined for the first time, and the NR1D1 protein can be used as a key marker for evaluating the secondary nerve injury degree of the hemorrhagic cerebral apoplexy and developing treatment and / or alleviation of the hemorrhagic cerebral apoplexy; a specific antigen peptide and an antibody for accurately detecting the NR1D1 protein phosphorylation site are further constructed, and an efficient tool is provided for molecular evaluation of hemorrhagic stroke secondary nerve injury; meanwhile, polypeptide molecules capable of inhibiting NR1D1 protein phosphorylation are researched and developed, through the dual effects of specifically blocking the phosphorylation process and reducing protein degradation, necrosis of brain tissues around hematoma after hemorrhagic cerebral apoplexy is relieved, secondary dyskinesia is improved, and the effect of inhibiting NR1D1 protein phosphorylation is achieved. And a brand new scheme is provided for molecular evaluation and targeted intervention of hemorrhagic stroke secondary nerve injury.

The invention relates to the technical field of intelligent medical prediction, in particular to an intelligent early warning method and system for adverse reactions of chemotherapy medication of tumor patients, and the method comprises the steps: inputting gene sequencing data and time sequence physiological index data of a current patient into a network model, and outputting an injury stage by the network model; the training data set of the network model comprises gene sequencing data, time sequence physiological index data and injury stages; the acquisition process of the injury stage comprises the following steps: acquiring the relative metabolic rate of the gene sequencing data to chemotherapeutics, and further determining the relative speed of in-vivo toxicity accumulation of the gene sequencing data; after time sequence physiological index data of meaningless physiological fluctuation of a historical patient is smoothed, a nerve injury change curve is obtained according to the time sequence physiological index data, whether a potential subclinical signal segment exists in the nerve injury change curve or not is recognized, and if yes, the injury stage is judged according to the potential subclinical signal segment. According to the method, individualized and accurate risk prediction can be carried out before irreversible nerve injury caused by chemotherapy occurs.

Disclosed in the present invention is the use of a mesenchymal-stem-cell-derived intracellular nanovesicle in neuroprotection. Compared to a small extracellular vesicle with exosomes as the main component, the small intracellular nanovesicle of the present invention has a smaller particle size, a narrower particle size distribution range, and greater stability at different temperatures, and has good tissue compatibility. The small intracellular nanovesicle of the present invention can better ameliorate nerve injury or neurodegenerative diseases such as optic nerve injury, ischemic stroke and Alzheimer's disease, and has very good application and research value in the field of pharmaceuticals.

The invention discloses an application of baricitinib in treatment of cerebral arterial thrombosis, and the baricitinib is used as a neuroprotective agent and is applied to treatment of cerebral arterial thrombosis after large vascular occlusion. The application of the invention reduces neuroinflammatory response, reduces nerve injury, protects nerves, improves stroke prognosis, and improves treatment effect.

This invention relates to a synergistic composition comprising combination of palmitoylethanolamide, Acetyl carnitine, and uridine, or their pharmaceutically acceptable salts, derivatives, isomers, or deacetylated form thereof for controlling neuromuscular pain and repairing nerve damage. The present invention provides a synergistic composition for the management of nerve health. The invention specifically provides a composition that exhibits a synergistic effect and demonstrates therapeutic effectiveness comparable to standard chemical drug.

The present invention relates to a biomarker composition for diagnosing stroke or post-stroke neurological damage, for diagnosing the severity of stroke or post-stroke neurological damage, and for predicting stroke prognosis, and the like. Using an ischemic stroke mouse disease model, a tissue damage analysis and a behavioral analysis were performed, and the mRNA level expression was confirmed, and as a result, Prox1 or Dcx could be selected as a biomarker. In addition, it was confirmed that the expression of Prox1 or Dcx increased as the severity of stroke or post-stroke neurological damage was higher, and thus the present invention is expected to be useful for diagnosing stroke or post-stroke neurological damage, for diagnosing the severity of stroke or post-stroke neurological damage, and for predicting stroke prognosis.

The utility model discloses a radial artery hemostat with timing and reminding functions, belongs to the technical field of medical auxiliary instruments, and aims to solve the problems that as the radial artery hemostat does not have the timing and reminding functions, nerve injury can occur and the occurrence rate of radial artery occlusion can be increased after the radial artery hemostat compresses the radial artery for a long time. Elastic bands are hinged to the two sides of the fixing plate, a threaded rod is installed at the top end of the fixing plate in a threaded mode, a pressurizing block is rotatably installed at the bottom end of the threaded rod, a screwing head is fixedly installed at the top end of the threaded rod, and installation blocks are fixedly installed at the positions, located on the two sides of the threaded rod, of the top end of the fixing plate; limiting grooves are formed in the opposite sides of the mounting grooves; through the arrangement of the electronic timer and the loudspeaker, medical staff can time conveniently when a patient uses the radial artery hemostat, the use time of the radial artery hemostat can be controlled conveniently, and the situation that the radial artery hemostat is used for a too long time and influences the radial artery of the patient is avoided as much as possible.

This invention relates to a juglansin and lipoic acid conjugate, its preparation method, and its applications. The juglansin and lipoic acid conjugate is named CL-1. CL-1 exhibits significant protective effects in models of oxidative and inflammatory damage in nerve cells, with a significantly greater reduction in TNF-α and IL-6 levels than the monomeric juglansin and lipoic acid, indicating that CL-1 has superior anti-inflammatory and anti-neural damage effects compared to the monomeric drugs, and possesses the potential to treat neurodegenerative diseases such as Alzheimer's disease. The provided preparation method is designed specifically for the structural characteristics of juglansin and lipoic acid, enabling efficient and large-scale synthesis of CL-1.

The present invention belongs to the field of biomedical technology, and particularly relates to the use of dendritic cells in the prevention and / or treatment of demyelinating diseases. The expression level of Talin1 protein in the dendritic cells is reduced or not expressed. Loading the dendritic cells with myelin peptides can safely and effectively alleviate immune inflammation and nerve damage, and thus is expected to develop into a new therapy for the prevention and / or treatment of demyelinating diseases.

The invention belongs to the field of medicines, and particularly relates to application of an RGCs activity protection component in preparation of a medicine for preventing and / or treating optic nerve injury, and the RGCs activity protection component is a compound with a structure # imgabs0 # as shown in a formula 1 and a crystal of the compound. In the formula 1, R1 to R3 are independently H or alkyl groups of C1 to C3. Researches show that the formula 1 can be used as an RGCs activity protection component, can effectively promote regeneration of injured optic nerves and improve the survival rate of optic ganglion cells after optic nerve injury, and is beneficial to prevention and / or treatment of optic nerve injury diseases caused by various causes.

To provide therapeutic agents more effective in the treatment of neurological disorders comprising a culture supernatant of mesenchymal stem cells.SOLUTION: The invention provides a therapeutic agent for a neurological disorder, where the therapeutic agent comprises a culture supernatant of a mesenchymal stem cell and / or a cell capable of differentiating to a mesenchymal stem cell, and the agent is used in combination with a stimulation to the nerve of a patient, where the stimulation is preferentially applied to one or more sites selected from the group consisting of a nerve injury site, a site around a nerve injury and a site that compensates the function of the nerve injury site.SELECTED DRAWING: None

The present invention relates to the technical field of biomaterial preparation, and in particular to an adhesive hydrogel with anti-inflammatory, antioxidant and pro-angiogenic capabilities and its application. The adhesive hydrogel of the present invention comprises an anti-adhesion layer, an adhesion layer and an inner layer arranged in sequence; the anti-adhesion layer and the adhesion layer are respectively formed by cross-linking ACG solutions of different pH values; the inner layer uses methacrylate whey protein as a base material and is loaded with EGCG@DEX‑PBAP. The adhesive hydrogel can be used for the repair of skin damage, muscle damage, nerve damage, and myocardial damage tissue.

The invention discloses a preparation method of a transplantable cell strain for treating Parkinson's disease, which comprises the following steps: injecting pluripotent stem cells into animal body tissues, and inducing through a tissue microenvironment. According to the method, the uniqueness of in-vivo tissues is utilized, so that the stem cells are finally proliferated and differentiated into the nerve-like precursor cells capable of being transplanted for treating the Parkinson's disease, a large number of transplantable cells can be efficiently, conveniently and safely obtained through the method, and the method is used for solving the problem that the source and the number of cells are limited in previous cell transplantation. And a new possibility is provided for treatment of nerve injury diseases.

The invention discloses an aromatic alkylamine ferroptosis inhibitor based on a butylphthalide structure and a preparation method and application thereof. The chemical structural formula of the ferroptosis inhibitor is shown as a formula 1 or a formula 2. The ferroptosis inhibitor can inhibit ferroptosis caused by a ferroptosis inducer and can reduce the level of active oxygen in cells. Nerve injury caused by cerebral ischemia reperfusion can be relieved, and symptoms of neurological diseases such as Alzheimer's disease and Parkinson's disease can be relieved; compared with a ferroptosis inhibitor Ferrostatin-1, the aryl alkyl amine compound disclosed by the invention has better metabolic stability and is suitable for in-vivo drug effect evaluation. Therefore, the novel aryl alkyl amine compound provided by the invention has a very good application value in treatment of neurological diseases related to ferroptosis.